Non-interventional, Observational, Long Term Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel (ATG) Treatment in Patients With Acromegaly.
Phase of Trial: Phase IV
Latest Information Update: 16 Jan 2019
Price : $35 *
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Pharmacodynamics
- Acronyms TAPAS
- Sponsors Ipsen
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 03 Nov 2014 Planned End Date changed from 1 Jul 2020 to 1 Aug 2020 as reported by ClinicalTrials.gov record.